View Cart (0 items)

ARIAD names Martin J. Duvall as senior vice president, commercial operations

September 06, 2011
/ Print / Reprints /
| Share More
/ Text Size+

CAMBRIDGE, Mass. — ARIAD Pharmaceuticals has named Martin J. Duvall as senior vice president, commercial operations, according to a press release.

Duvall will be responsible for leading the global commercialization of ARIAD''s innovative oncology drug candidates, including its investigational pan-BCR-ABL inhibitor, ponatinib, which is in a pivotal Phase 2 clinical trial in patients with resistant or intolerant chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia.

“Marty has demonstrated unequivocal success in both U.S. and international oncology leadership roles, working in both large pharmaceutical and mid-sized biotechnology companies on drugs to treat both solid tumors and hematological cancers,” said Harvey J. Berger, chairman and CEO of ARIAD. “He has the global experience, leadership skills and dedication that we need to maximize the value of ponatinib and our pipeline of oncology drug candidates for our shareholders and the entrepreneurial know-how needed to build a ''second-to-none'' commercial organization.”
You must login or register in order to post a comment.